hummm,,,Koo,,since MD has compared us to Denali,,,,and noted that such valuations are possible for biotech research companies who trade south of the boarder,,,there seems to be a disconnect in regards to acheiving a much higher share pricing/market capitalization than counterparts on oblique exchanges. The statement seems to be accurate,,,,,,,and KBC,,as far as where its market cap has been is hind sight,,,,,,I can figure that out,,,however history is very important as you note,,but,,its the foresight that counts!!!,,the post was just for info to those interested.